Adaptive Biotechnologies Corporation
Income Statement
| Line Item | FY2017 |
|---|---|
| Revenue | $38.4M |
| MRD | — |
| Immune Medicine | — |
| Cost of Revenue | $15.7M |
| Gross Profit | $22.8M |
| Gross Margin | 59.2% |
| Operating Expenses | |
| Research & Development | $32.0M |
| SG&A Expense | $15.9M |
| Operating Income | $-44.5M |
| Operating Margin | -115.7% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-42.8M |
| Net Margin | -111.4% |
| EPS (Basic) | $-3.50 |
| EPS (Diluted) | $-3.50 |
| Shares Outstanding (Basic) | — |
| Shares Outstanding (Diluted) | — |
| Dividends Per Share | — |